Nuwellis Inc vs Palantir Technologies Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Palantir Technologies Inc trades at $208.46 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 217127.3× Nuwellis Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Palantir Technologies Inc for 78 Days on average.
| NUWE | PLTR | |
|---|---|---|
Market Cap | $2.20M | $477.68B |
Volume | 121,544 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $146.65 | $207.18 |
52-Week Low | $0.68 | $107.27 |
Typical Hold Time | 26 Days | 78 Days |
Enterprise Value | -$1.52M | $468.48B |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Palantir (PLTR) trades at $209.05, up 7.74% with strong bullish momentum as it approaches resistance at $209. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025, net income margin expanding to 36.3%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support the upward trend, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02.
Outlook remains positive given accelerating AI adoption and strong commercial growth (149% YoY US commercial revenue). Key risks include premium valuation sensitivity and competitive AI market pressures. Analyst consensus at $191.69 suggests potential near-term consolidation, but continued execution could justify higher multiples. Cash flow trends show strong operational performance despite significant investing outlays.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →